Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Planning and Dissemination Grant - Institute Community Support

University of British Columbia

$20,000.00

Severe Cutaneous Adverse Drug Reactions (SCAR) 2019 International Meeting: From Science to Translation

FY 2017-18

Summary
Severe skin reactions, such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), are immune system-mediated reactions caused by commonly used drugs such as painkillers and antiepileptic drugs. Although these reactions are rare, they represent a significant burden to those affected, leading to death in >30% of cases, and significant health consequences for surviving patients. These severe skin reactions are associated with high mortality rates (>30%) and significant short and long-term morbidity. Advancement in SJS/TEN research, prevention and clinical care within Canada and internationally requires an interdisciplinary approach, including health care providers, clinical and basic researchers. This proposal seeks support for the 2nd international SJS/TEN meeting "Severe Cutaneous Adverse Drug Reactions (SCAR) 2019: From Science to Translation" to address the numerous unmet needs of SJS/TEN. The meeting will take place April 26-27, in Vancouver, BC and will encourage the participation of clinicians, researchers, patients and patient advocates. The two-day program will feature more than 20 national and international experts and will include keynote speaker presentations, round table discussions and a trainee-focused poster session. This meeting will serve to 1) Assemble an interdisciplinary global network of key opinion leaders, regulatory authorities, and patients to learn about and to formulate plans to address the unmet needs in SJS/TEN; 2) The proceedings of this meeting will be disseminated through web-recording and will help develop educational materials for patients, clinicians, scientific publications and clinical guidelines; 3) Help develop and launch the predictive pharmacogenomic tests as a precision medicine tool to lower the occurrence of SJS/TEN reactions. Together, this meeting will fuel significant advancement in understanding the causes, treatment and prevention of SJS/TEN.
Program
Planning and Dissemination Grant - Institute Community Support
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
383781
Name
Carleton Bruce C
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Genetics
Theme2
Clinical
Prcname2
Planning and Dissemination - Institute of Genetics
Projecttitle
Severe Cutaneous Adverse Drug Reactions (SCAR) 2019 International Meeting: From Science to Translation
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Genetics; Immunology; Patient Care; Pharmacogenomics Testing; Precision Medicine; Predictive Biomarkers; Scientific Meeting; Serious Cutaneous Adverse Drug Reactions; Steven Johnson Syndrome; Toxic Epidermal Necrolysis
Abstract
Severe skin reactions, such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), are immune system-mediated reactions caused by commonly used drugs such as painkillers and antiepileptic drugs. Although these reactions are rare, they represent a significant burden to those affected, leading to death in >30% of cases, and significant health consequences for surviving patients. These severe skin reactions are associated with high mortality rates (>30%) and significant short and long-term morbidity. Advancement in SJS/TEN research, prevention and clinical care within Canada and internationally requires an interdisciplinary approach, including health care providers, clinical and basic researchers. This proposal seeks support for the 2nd international SJS/TEN meeting "Severe Cutaneous Adverse Drug Reactions (SCAR) 2019: From Science to Translation" to address the numerous unmet needs of SJS/TEN. The meeting will take place April 26-27, in Vancouver, BC and will encourage the participation of clinicians, researchers, patients and patient advocates. The two-day program will feature more than 20 national and international experts and will include keynote speaker presentations, round table discussions and a trainee-focused poster session. This meeting will serve to 1) Assemble an interdisciplinary global network of key opinion leaders, regulatory authorities, and patients to learn about and to formulate plans to address the unmet needs in SJS/TEN; 2) The proceedings of this meeting will be disseminated through web-recording and will help develop educational materials for patients, clinicians, scientific publications and clinical guidelines; 3) Help develop and launch the predictive pharmacogenomic tests as a precision medicine tool to lower the occurrence of SJS/TEN reactions. Together, this meeting will fuel significant advancement in understanding the causes, treatment and prevention of SJS/TEN.
Competitiondate
201803
Approvedterm2
1 yr 0 mth
Pinamesdelim
Carleton, Bruce C
Approvedterm
1 an 0 mois
Cihrcontribution2
Institute of Genetics~ $20,000~ $0~